Upside case
Bull case
—
The bull case requires both strong earnings delivery and the market pricing RGC more generously than it does today.
Analysis OverviewHoldUpdated May 1, 2026
Regencell Bioscience Holdings Limited (RGC) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Hold
Covering
4
analysts
0 bullish · 0 bearish · 4 covering RGC
Strong Buy
0
Buy
0
Hold
4
Sell
0
Strong Sell
0
Consensus Target
—
— vs today
Scenario Range
— – —
Model bear to bull value window
Coverage
4
Published analyst ratings
Valuation Context
—
Forward P/E · Market cap $13.6B
RGC price targets
Three scenarios for where RGC stock could go
Current
~$28
Confidence
—
Updated
May 1, 2026
Market caseClosest to today
Base case
—
The base case reflects analyst consensus expectations — steady delivery without requiring a major catalyst or re-rating.
Stress case
Bear case
—
The bear case reflects a scenario where earnings shortfalls or multiple compression combine to materially reduce the stock from its current level.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Regencell Bioscience Holdings Limited
RGC · NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Regencell Bioscience is a Traditional Chinese medicine bioscience company that researches, develops, and commercializes TCM treatments for neurocognitive disorders like ADHD and autism. It generates revenue primarily from product sales of its TCM formulations, though as an early-stage company it may still be in development phase with limited commercial revenue. Its competitive advantage lies in combining traditional Chinese medicine with modern bioscience research to address neurocognitive conditions with limited pharmaceutical options.
Market Cap
$13.6B
Revenue TTM
$0
Net Income TTM
-$5M
RGC Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
—No data
10 quarters tracked
Revenue Beat Rate
—No data
vs consensus estimates
Avg EPS Surprise
—
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q1 2024
Q1 2025
Q2 2025
Q4 2025
Last 4 Quarters
EPS beats: 0 of 4Q1 2024
EPS
$0.00/—
Revenue
—/—
Q1 2025
EPS
$-0.14/—
Revenue
—/—
Q2 2025
EPS
$-0.14/—
Revenue
—/—
Q4 2025
EPS
$-0.00/—
Revenue
—/—
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q1 2024 | $0.00/— | — | —/— | — |
| Q1 2025 | $-0.14/— | — | —/— | — |
| Q2 2025 | $-0.14/— | — | —/— | — |
| Q4 2025 | $-0.00/— | — | —/— | — |
Next Earnings
—
Expected EPS
—
Expected Revenue
—
RGC beat EPS estimates in 0 of 4 tracked quarters. Mixed delivery makes the upcoming report a key data point for re-rating.
RGC Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Relative Valuation
Benchmark comparison across market, sector, and history below.
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
RGC
-3171.3x
vs
S&P 500
25.2x
12670% discount
vs Healthcare Trailing P/E
RGC
-3171.3x
vs
Healthcare
22.1x
14421% discount
vs RGC 5Y Avg P/E
Today
-3171.3x
vs
5Y Average
—
Benchmark unavailable
Forward PE
—
S&P 500
19.1x
—
Healthcare
19.0x
—
5Y Avg
—
—
Trailing PE
-3171.3x
S&P 500
25.2x
-12670%
Healthcare
22.1x
-14421%
5Y Avg
—
—
PEG Ratio
—
S&P 500
1.75x
—
Healthcare
1.52x
—
5Y Avg
—
—
EV/EBITDA
—
S&P 500
15.3x
—
Healthcare
14.1x
—
5Y Avg
—
—
Price/FCF
—
S&P 500
21.3x
—
Healthcare
18.7x
—
5Y Avg
—
—
Price/Sales
—
S&P 500
3.1x
—
Healthcare
2.8x
—
5Y Avg
—
—
Dividend Yield
—
S&P 500
1.88%
—
Healthcare
1.40%
—
5Y Avg
—
—
| Metric | RGC | S&P 500 | Healthcare | 5Y Avg RGC |
|---|---|---|---|---|
| Forward PE | — | 19.1x | 19.0x | — |
| Trailing PE | -3171.3x | 25.2x-12670% | 22.1x-14421% | — |
| PEG Ratio | — | 1.75x | 1.52x | — |
| EV/EBITDA | — | 15.3x | 14.1x | — |
| Price/FCF | — | 21.3x | 18.7x | — |
| Price/Sales | — | 3.1x | 2.8x | — |
| Dividend Yield | — | 1.88% | 1.40% | — |
RGC trades above S&P 500 benchmarks on 0 of 1 measured multiples — appears modestly priced relative to the S&P 500 on most measures.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolRGC Financial Health
Verdict
Stressed
Key financial metrics for RGC are shown below.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$0
Revenue Growth
TTM vs prior year
+100.0%
Gross Margin
Gross profit as a share of revenue
—
Operating Margin
Operating income divided by revenue
—
Net Margin
Net income divided by revenue
—
EPS (TTM)
Diluted earnings per share, trailing twelve months
$-0.35
Free Cash Flow (TTM)
Cash generation after capex
-$7M
FCF Margin
FCF as share of revenue — the primary cash quality signal
—
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
-43.8%
ROA
Return on assets, trailing twelve months
-60.2%
Cash & Equivalents
Liquid assets on the balance sheet
$3M
Net Cash
Cash exceeds total debt — no net leverage
$3M
Debt Serviceability
Net debt as a multiple of annual free cash flow
Net cash ✓
ROE *
Return on equity, trailing twelve months
-67.0%
* Elevated by buyback-compressed equity — compare ROIC (-43.8%) for an undistorted picture of capital efficiency.
Shareholder Returns
How capital is returned to owners
Total shareholder yield
0.0%
Dividend
—
Buyback
0.0%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$0
Dividend / Share
Annualized trailing dividend per share
—
Payout Ratio
Share of earnings distributed as dividends
—
Shares Outstanding
Current diluted share count
494M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt). ROE marked * where buyback-compressed equity base may inflate the figure.
Open full ratios pageRGC Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated April 29, 2026
High Risk
Lack of Revenue and Profitability
Regencell Bioscience Holdings (RGC) has reported zero revenue in recent periods and has a significant retained earnings deficit, indicating historical challenges with profitability. The company's price-to-book ratio is considered very high, suggesting investors are paying a premium for future growth prospects despite current earnings.
High Risk
Material Weaknesses in Internal Controls
The company's 20-F filing revealed three material weaknesses in internal controls over financial reporting, including a lack of knowledge, inadequate risk assessment protocols, and failure to segregate financial duties. These weaknesses could lead to significant financial misstatements and regulatory scrutiny.
High Risk
High Valuation Despite Lack of Assets
Despite having no revenue, assets, or business activity, RGC has maintained a substantial market capitalization, leading to concerns of severe overvaluation. This disconnect between market cap and actual business fundamentals poses a high risk to investors.
High Risk
Extreme Share Price Volatility
RGC's share price has experienced extreme volatility, with significant surges and declines attributed to speculative trading and potential 'short squeezes'. This volatility can lead to unpredictable investment outcomes and increased risk for shareholders.
Medium
Low Liquidity
Concerns about low market liquidity exist, which could impact investors' ability to liquidate their investments at a favorable price. Low liquidity can exacerbate price volatility and increase the risk of significant losses.
Medium
Speculative Trading
Much of the stock's rally is attributed to speculative trading and algorithmic trading rather than sustainable revenue or earnings growth. This speculative nature increases the risk of sudden price corrections.
Medium
Early-Stage Bioscience Company
As an early-stage bioscience company, RGC operates in a high-risk sector with inherent clinical trial and regulatory challenges. The success of its products is uncertain and could lead to substantial financial losses.
Lower
Foreign Private Issuer Status
As a foreign private issuer, RGC is permitted to adopt certain home country corporate governance practices that may differ from Nasdaq's standards. This could lead to potential governance issues that may not align with investor expectations.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why RGC Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated April 29, 2026
Innovative Approach
Regencell Bioscience Holdings is focusing on Traditional Chinese Medicine (TCM) to address neurocognitive disorders such as ADHD and Autism Spectrum Disorder (ASD). This innovative approach could tap into a novel and potentially lucrative market if the treatments prove effective.
Clinical Trial Progress
Recent clinical trials have shown promising results, with reported symptom improvements of up to 37%. This level of efficacy is a critical driver for biotech companies and could enhance investor confidence in RGC's future prospects.
Momentum and Speculation
RGC has seen a staggering year-to-date price increase of 14,899% as of June 2025. This dramatic momentum, fueled by speculative trading and AI-driven tools, may attract further investment and interest in the stock.
Technical Indicators
Technical analyses indicate a 'Strong Buy' outlook based on moving averages, suggesting a potential for continued upward trends. There is an 89% probability of a continued uptrend indicated by MACD crossovers and momentum shifts.
Market Interest and Volatility
The stock has experienced intense trading activity and significant price swings, which have drawn attention from traders. While this volatility carries risks, it also presents opportunities for short-term gains.
Potential for Growth
Despite having zero revenue in recent years, projections indicate significant future revenue and EBITDA potential, especially with the possibility of a Nasdaq listing on the horizon.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
RGC Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$27.59
52W Range Position
31%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$2.62
+953.1% from the low
52-Week High
$83.60
-67.0% from the high
1 Month
-10.51%
3 Month
+1.32%
YTD
+34.3%
1 Year
+595.0%
3Y CAGR
+243.6%
5Y CAGR
+151.1%
10Y CAGR
+58.5%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
RGC vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
—
vs 2.8x median
Peer median unavailable
Revenue Growth
+100.0%
vs -2.9% median
+3602% above peer median
Net Margin
—
vs -7.6% median
Peer median unavailable
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
RGC RGC Regencell Bioscience Holdings Limited | $13.6B | — | +100.0% | — | Hold | — |
NUV NUVB Nuvation Bio Inc. | $1.7B | — | +47.2% | -102.1% | Buy | +146.0% |
AEY AEYE AudioEye, Inc. | $95M | — | +14.5% | -7.6% | — | — |
SIG SIGA SIGA Technologies, Inc. | $337M | 2.8x | -20.2% | 24.6% | Buy | — |
ATH ATHA Athira Pharma, Inc. | $17M | — | — | — | — | — |
PRA PRAX Praxis Precision Medicines, Inc. | $7.6B | — | -25.7% | — | Buy | +61.1% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
RGC Dividend and Capital Return
RGC does not currently return meaningful capital to shareholders.
Dividend UnknownFCF Unknown
Total Shareholder Yield
0.0%
Dividend + buyback return per year
Buyback Yield
0.0%
Dividend Yield
—
Payout Ratio
—
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.00
Growth Streak
Consecutive years of dividend increases
0Y
3Y Div CAGR
—
5Y Div CAGR
—
Ex-Dividend Date
—
Payment Cadence
Annual
0 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$0
Estimated Shares Retired
0
Approx. Share Reduction
0.0%
Shares Outstanding
Current diluted share count from the screening snapshot
494M
| Year | Div / Share | YoY Grw |
|---|---|---|
| 2018 | $0.22 | -75.0% |
| 2017 | $0.88 | 0.0% |
| 2016 | $0.88 | 0.0% |
| 2015 | $0.88 | 0.0% |
| 2014 | $0.88 | +4.8% |
FAQ
5 questionsRGC Investor Questions
Common questions answered from live analyst data and company financials.
01Is Regencell Bioscience Holdings Limited (RGC) stock a buy or sell in 2026?
Regencell Bioscience Holdings Limited (RGC) is rated Hold by Wall Street analysts as of 2026. Of 4 analysts covering the stock, 0 rate it Buy or Strong Buy, 4 rate it Hold, and 0 rate it Sell or Strong Sell.
02Is Regencell Bioscience Holdings Limited (RGC) stock overvalued in 2026?
Forward earnings data for RGC is not currently available. Review the valuation table above for trailing P/E, EV/EBITDA, and price-to-sales comparisons against market and sector benchmarks.
03What are the main risks for Regencell Bioscience Holdings Limited (RGC) stock in 2026?
The primary risks for RGC in 2026 are: (1) Lack of Revenue and Profitability — Regencell Bioscience Holdings (RGC) has reported zero revenue in recent periods and has a significant retained earnings deficit, indicating historical challenges with profitability. (2) Material Weaknesses in Internal Controls — The company's 20-F filing revealed three material weaknesses in internal controls over financial reporting, including a lack of knowledge, inadequate risk assessment protocols, and failure to segregate financial duties. (3) High Valuation Despite Lack of Assets — Despite having no revenue, assets, or business activity, RGC has maintained a substantial market capitalization, leading to concerns of severe overvaluation. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
04When does Regencell Bioscience Holdings Limited (RGC) report its next earnings?
A confirmed upcoming earnings date for RGC is not yet available. Check the Earnings section above for the most recent quarterly report dates and forward estimates.
05How much free cash flow does Regencell Bioscience Holdings Limited generate?
Regencell Bioscience Holdings Limited (RGC) had a free cash outflow of $7M in free cash flow over the trailing twelve months. RGC returns capital to shareholders through and share repurchases ($0 TTM).